Результаты поиска - Dongchu Zhou

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China по Dongchu Zhou, Xia Luo, Zhen Zhou, Xiaohui Zeng, Xiaomin Wan, Chongqing Tan, Qiao Liu

Connect to this object online.